Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 28, 2008

Aerovance Closes $10M Financing Round

  • Aerovance secured $20 million in venture debt financing. Aerovance says that it drew down $10 million from the financing line at closing. The remaining $10 million is available upon the achievement of corporate milestones.

    The money will support development of Aerovant, which is in Phase IIa studies for asthma. Aerovant is a recombinant human IL-4 variant that is an inhibitor of both the IL-4 and IL-13 receptors.

    Oxford Finance Corporation led the syndicate, which includes Silicon Valley Bank and Comerica Bank.

  • You’re all set! Thank you for subscribing to GEN Highlights.